What Stage Is High-Grade Urothelial Carcinoma?

High-grade urothelial carcinoma is not confined to a single stage. “High-grade” describes how abnormal and aggressive the cancer cells look under a microscope, while “stage” describes how far those cells have spread through the bladder wall and beyond. A high-grade urothelial carcinoma can be stage Ta (still on the bladder’s inner lining), T1 (into the layer just beneath the lining), carcinoma in situ (flat but high-grade by definition), T2 through T4 (into and through the muscle wall), or metastatic. The confusion is understandable because grade and stage are deeply intertwined in this cancer, but they are not the same thing, and the distinction matters for every treatment decision that follows.

Why Grade and Stage Are Often Confused

When a pathologist examines bladder tumor tissue, they assign both a grade and a stage. Grade reflects how disordered the cells appear compared with normal urothelial cells. Low-grade tumors still resemble normal tissue and tend to grow slowly. High-grade tumors look strikingly abnormal and are more likely to invade deeper layers and spread. The most recent World Health Organization classification, updated in 2022, refines how pathologists distinguish these categories and how they handle tumors that show mixed features.¹

Stage, by contrast, refers to how deeply the tumor has penetrated the bladder wall and whether it has reached lymph nodes or distant organs. The bladder wall has distinct layers: the innermost urothelial lining, then a connective tissue layer called the lamina propria, then the thick muscular wall (muscularis propria), then fat and surrounding structures. A tumor’s T-stage tracks its progress through these layers. A high-grade tumor can sit in any of them. What makes the pairing so common is biological: high-grade cells are far more likely than low-grade cells to push deeper, so by the time a cancer is muscle-invasive, it is almost always high-grade.

Non-Muscle Invasive but Still Dangerous

Roughly three-quarters of bladder cancers are caught before they invade the muscle wall. These non-muscle invasive bladder cancers include stage Ta (papillary tumors confined to the urothelial surface), stage T1 (tumors that have breached into the lamina propria), and carcinoma in situ (CIS), a flat lesion that is high-grade by definition. Among these, T1 high-grade tumors occupy an uneasy middle ground. They have not yet reached the muscle, which might suggest an early, manageable cancer, but their behavior can be anything but mild. The disease should be considered aggressive and potentially lethal.²

The problem with T1 high-grade tumors is their tendency to recur and progress. They have a higher incidence of recurrence and progression than other non-muscle invasive bladder cancers, which means that vigilant monitoring is not optional but essential.³ “Progression” here has a specific and ominous meaning: the tumor advances into the muscle wall, converting a non-muscle invasive cancer into a muscle-invasive one that requires far more aggressive treatment.

Carcinoma in situ deserves special mention. CIS is always high-grade, yet it is flat rather than papillary, so it does not form an obvious mass. It can be easy to miss on cystoscopy. Although CIS is typically grouped with other non-muscle invasive bladder cancers, its higher grade and aggressiveness make it a unique clinical entity.⁴ If left untreated, CIS carries a substantial risk of progressing to invasive cancer.

The Upstaging Problem

One of the trickiest aspects of high-grade bladder cancer is that the stage determined at the time of initial biopsy often turns out to be wrong, and almost always wrong in the dangerous direction. Transurethral resection, the procedure that both removes visible tumor and provides tissue for staging, can miss deeper invasion. When the initial biopsy of a T1 tumor does not include muscle tissue in the specimen, there is no way to confirm whether cancer has already reached the muscle. In one study of patients whose biopsies were staged at T1, those whose specimens lacked muscle tissue were upstaged to muscle-invasive disease at far higher rates when the bladder was later removed surgically.⁵

This is why guidelines strongly recommend a repeat resection for anyone initially diagnosed with T1 high-grade disease. The second look catches cancer that was incompletely removed or understaged the first time. If a patient is diagnosed with high-grade T1 at the initial transurethral resection, a second resection is strongly recommended regardless of whether the muscle layer was present in the first specimen.³ The re-resection confirms the stage and also ensures the site has been adequately cleared. For patients enrolled in studies tracking this process, the inclusion criteria typically require both a pathological diagnosis of T1 high-grade, adequate muscle tissue in the specimen, and a repeat resection.⁶

Imaging also plays a growing role in staging accuracy. Multiparametric MRI and the VI-RADS scoring system have been validated across multiple institutions as useful tools for local staging of bladder cancer, helping to distinguish non-muscle invasive from muscle-invasive disease before surgery.⁷ These imaging tools are particularly helpful when the initial biopsy leaves doubt about depth of invasion.

Muscle-Invasive Stages

Once a high-grade urothelial carcinoma has invaded the muscular wall of the bladder, it is classified as T2 (into the muscle), T3 (through the muscle into surrounding fat), or T4 (into nearby organs like the prostate, uterus, or pelvic wall). These muscle-invasive stages represent a fundamentally different disease from the non-muscle invasive forms. Treatment shifts from bladder-sparing approaches to radical cystectomy, meaning removal of the entire bladder, often combined with chemotherapy.

Neoadjuvant chemotherapy, given before surgery, is now a standard part of treatment for muscle-invasive urothelial carcinoma. The goal is to shrink the primary tumor and eliminate microscopic disease that may have already spread before it becomes detectable on scans.⁸ One concern with this approach is that the chemotherapy itself can cause anemia before surgery, which in turn may increase the need for blood transfusions around the time of the operation.⁹ New imaging approaches, such as novel PET tracers, are being studied to improve how accurately the extent of muscle-invasive disease is assessed before the bladder is removed.¹⁰

How Treatment Tracks With Stage

For non-muscle invasive high-grade disease, the cornerstone of treatment after tumor resection is intravesical therapy, where medication is instilled directly into the bladder. BCG immunotherapy, originally developed as a tuberculosis vaccine, has been used for this purpose for decades and remains the gold standard adjuvant treatment for high-risk and very high-risk non-muscle invasive bladder cancer.¹¹ BCG works by stimulating the immune system inside the bladder to attack residual cancer cells, reducing the risk of recurrence and decreasing the likelihood of progression to muscle-invasive disease.¹²

A typical BCG protocol involves weekly instillations for an initial induction course, followed by maintenance cycles over one to three years. In one large series, over 1,300 patients with T1 high-grade non-muscle invasive disease received adjuvant BCG therapy, with maintenance doses given at regular intervals over 36 months.¹³ Different BCG strains exist and have been studied for efficacy and tolerability, with at least one study demonstrating the clinical benefit of a six-weekly induction followed by monthly maintenance for one year.¹⁴

For muscle-invasive disease, as mentioned, treatment centers on radical cystectomy with or without neoadjuvant chemotherapy. If the cancer has already spread to lymph nodes or distant sites, systemic therapy becomes the primary approach. This is where immunotherapy with checkpoint inhibitors has opened new doors. Several checkpoint inhibitor drugs have been approved as first-line therapy for patients who cannot tolerate cisplatin-based chemotherapy, or as second-line therapy for metastatic urothelial carcinoma. Roughly 30% of patients with metastatic disease respond to these drugs, and some responses last longer than a year.¹⁵

Detecting High-Grade Urothelial Carcinoma

Urine cytology is one of the first tools used to identify high-grade urothelial carcinoma, and it works reasonably well for this grade. High-grade cells tend to be large, irregular, and easy for a cytopathologist to spot. In a study of patients with bladder diverticula, the sensitivity of urine cytology for detecting high-grade urothelial carcinoma was about 80%.¹⁶ That is significantly better than cytology’s sensitivity for low-grade tumors, which often shed cells that look nearly normal.

One diagnostic pitfall is that high-grade urothelial carcinoma cells can occasionally mimic normal umbrella cells, which are the large surface cells that naturally line the bladder. In one review, about 18% of confirmed malignant cases contained cancer cells resembling umbrella cells, and in a small fraction these mimics were the only type of abnormal cell present.¹⁷ This means a pathologist who is not looking carefully for subtle abnormalities could miss the cancer entirely.

When Variant Histology Changes the Picture

Not all urothelial carcinomas look the same under the microscope. Variant histologies are subtypes that differ in their microscopic appearance and, often, in their behavior. These include micropapillary, sarcomatoid, plasmacytoid, and small-cell variants, among others. All of these tend to be high-grade, and several carry a worse prognosis than conventional high-grade urothelial carcinoma. Micropapillary and sarcomatoid variants, for instance, are associated with poor outcomes, while squamous or glandular differentiation seems to have less effect on prognosis.¹⁸

The micropapillary variant is particularly worrying. These tumors are invariably high-grade and usually high-stage at diagnosis, frequently associated with lymphovascular invasion. The more micropapillary pattern present, the worse the prognosis tends to be, and when these tumors metastasize, the distant deposits are predominantly composed of this same aggressive pattern.¹⁹ Recognizing these variants on cytology or biopsy can prompt more aggressive surgical planning even at an earlier stage.²⁰ The presence of variant histology alone can warrant radical cystectomy in patients with T1 disease, where conventional high-grade urothelial carcinoma might still be managed with bladder-sparing therapy.¹⁸

Upper Tract Urothelial Carcinoma

Urothelial cells do not only line the bladder. They also line the renal pelvis (inside the kidney) and the ureters (the tubes connecting kidneys to the bladder). High-grade urothelial carcinoma can arise in any of these locations, and when it does, the staging principles are broadly similar but the clinical challenges differ. Upper tract tumors are harder to biopsy adequately, so clinical staging is much less reliable than in the bladder.

The gap between what clinicians think the stage is and what pathologists find after surgery is striking. In a large study, the concordance between biopsy-based clinical staging and final surgical pathology was only about 35%. Clinical understaging occurred in roughly 60% of patients, and among those diagnosed with non-muscle invasive disease before surgery, over 40% turned out to have muscle-invasive cancer on the final pathology specimen.²¹ Of patients ultimately found to have muscle-invasive disease, nearly 90% had been clinically diagnosed with a non-invasive stage beforehand.

Because of this staging gap, neoadjuvant chemotherapy has been explored for upper tract high-grade urothelial carcinoma as well. A nationally representative analysis found that patients with clinically non-organ-confined tumors who received chemotherapy before surgery had improved overall survival. Among those in the chemotherapy group with advanced clinical stage, about 27% had organ-confined disease at the time of surgery, compared with roughly 1% of those who went straight to surgery.²² That degree of downstaging suggests the chemotherapy is eliminating or shrinking disease that would otherwise be left behind.

Molecular Features and Immunotherapy Response

The molecular landscape of high-grade urothelial carcinoma has become clinically relevant, particularly for advanced or metastatic disease. Two of the most commonly altered genes in bladder cancer are TP53 and RB1, both of which play key roles in controlling cell growth. In a large molecular analysis, about 47% of urothelial carcinoma patients had alterations in at least one of these genes, and 17% had alterations in both simultaneously. Tumors with both RB1 and TP53 alterations had significantly higher tumor mutational burden and more predicted neoantigens, features that tend to make tumors more visible to the immune system.²³

This matters because it helps explain why some patients respond to checkpoint inhibitor immunotherapy and others do not. Tumors with higher mutational burden produce more abnormal proteins on their surfaces, giving the immune system more targets to recognize. When a checkpoint inhibitor removes the brakes that cancer uses to hide from the immune system, a highly mutated tumor is more likely to be recognized and attacked. This is part of why researchers are interested in molecular profiling for patients with advanced high-grade urothelial carcinoma: it may eventually guide which patients are most likely to benefit from immunotherapy versus conventional chemotherapy.

Dogs and the Future of Bladder Cancer Research

An unusual contributor to understanding muscle-invasive urothelial carcinoma is the domestic dog. Pet dogs develop invasive urothelial carcinoma naturally, not through laboratory induction, and their tumors closely mimic the human disease in cellular features, molecular subtypes, patterns of immune response, metastatic behavior, and response to therapy.²⁴ Gene expression studies have confirmed that canine tumors harbor the same luminal and basal transcriptional subtypes found in human muscle-invasive bladder cancer.²⁵

The practical value of this model is in drug testing. Most laboratory cancer models use artificially induced tumors in mice, which do not fully replicate the genetic diversity, immune microenvironment, or treatment resistance found in human patients. Dogs with naturally occurring bladder cancer develop the disease over years, with a functioning immune system and a realistic tumor microenvironment. Clinical trials in these dogs can help predict which targeted therapies and immunotherapies might succeed in human trials, potentially speeding up a drug development process that otherwise takes many years.²⁶ Several research groups are now running parallel studies in dogs and humans, testing new agents in both species to gather complementary data on safety and efficacy.